Ignite Creation Date:
2024-05-05 @ 11:50 PM
Last Modification Date:
2024-10-26 @ 10:40 AM
Study NCT ID:
NCT01433055
Status:
COMPLETED
Last Update Posted:
2019-08-28
First Post:
2011-07-21
Brief Title:
Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Schizophrenia is a devastating and costly illness One-third to one-half of people with schizophrenia do not respond to the most current drugs leaving clozapine as the best alternative for treatment However over 60 of people treated with clozapine continue to have persistent symptoms and cognitive impairments Little data is available to support evidence-based recommendations to guide clinicians in treating these patients Preliminary data has suggested that adjunct treatment with minocycline may offer robust symptom improvement in patients with schizophrenia including those taking clozapine Minocycline has had interesting effects including suggesting it may have a significant role in treatment of neurologic and psychiatric disorders Minocycline is currently available generically its side effects are well-described and minimal The proposed double-blind treatment study seeks to demonstrate that adjunctive minocycline offers patients superior efficacy for persistent positive symptoms cognitive impairments andor other components of schizophrenia pathology This knowledge could lead to the more effective treatment of patients with schizophrenia The research itself may lead to a better understanding of the pathophysiology of positive symptoms and cognitive impairments which could contribute to improved treatments in the future
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R21MH091184-01A1 | NIH | None | httpsreporternihgovquickSearch1R21MH091184-01A1 |